NCT07476287 2026-03-17
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
Phase 2 Not yet recruiting
Clinical Trials
34 trialsNCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT07465757 2026-03-12
ALISCA-Lung2
Puma Biotechnology, Inc.
Phase 2 Not yet recruiting
NCT07459634 2026-03-10
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT07402343 2026-03-04
T-BRAIN
Maastricht University Medical Center
Phase 2 Not yet recruiting
NCT07398560 2026-02-10
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
The Third Affiliated Hospital of Harbin Medical University
Phase 2 Not yet recruiting
NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07357532 2026-01-22
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07253142 2025-12-02
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Shanghai Henlius Biotech
Phase 2 Not yet recruiting
NCT07200154 2025-09-30
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07103408 2025-08-05
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07097948 2025-08-01
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07076914 2025-07-22
PPI-PROTECT
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Not yet recruiting
NCT07076095 2025-07-21
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2 Not yet recruiting
NCT07069270 2025-07-16
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07055581 2025-07-09
Durvalumab as Consolidation for Patients LS-SCLC
Tongji Hospital
Phase 2 Not yet recruiting
NCT07004712 2025-06-08
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06914050 2025-04-25
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06909383 2025-04-03
Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
Guangzhou Institute of Respiratory Disease
Phase 2 Not yet recruiting
NCT06786312 2025-01-22
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06784206 2025-01-20
Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06724263 2024-12-09
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Tasly Biopharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT06648200 2024-10-18
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06614621 2024-09-26
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06497543 2024-09-19
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT06554535 2024-08-15
Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT06497530 2024-07-12
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Not yet recruiting
NCT06478043 2024-07-08
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06375109 2024-04-19
NeoSCLC-001
Beijing Chest Hospital, Capital Medical University
Phase 2 Not yet recruiting
NCT06306560 2024-03-12
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
Phase 2 Not yet recruiting
NCT06236997 2024-02-01
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05703997 2023-01-30
FASTIMMUNE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting
NCT05484583 2022-08-05
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting